Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-3005PMID 22661587PMCID PMC4030710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

  2011cited by this paper
• Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

  2009cited by this paper
• Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

  2009cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

  2008cited by this paper
• Molecular pathobiology of gastrointestinal stromal sarcomas.

  2008cited by this paper
• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  2006cited by this paper
• Angiogenesis inhibitors and hypertension: an emerging issue.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

  2006cited by this paper
• Estimating treatment effects in randomized trials with treatment switching.

  2006cited by this paper
• Uses and limitations of randomization-based efficacy estimators

  2005cited by this paper
• SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

  2004cited by this paper
• Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003cited by this paper
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper

• Optimal Sunitinib Dosing Based on Platelet Count in an Older Patient With Gastrointestinal Stromal Tumor

  2025cites this paper
• Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.

  2025cites this paper
• Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

  2025cites this paper
• Therapeutic Strategies after Imatinib Resistance in Gastrointestinal Stromal Tumors

  2025cites this paper
• Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs

  2025cites this paper
• A novel risk score after neoadjuvant imatinib predicts relapse-free survival in patients with gastrointestinal stromal tumours (GIST).

  2025cites this paper
• Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries

  2024cites this paper
• Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

  2024cites this paper
• Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update

  2024cites this paper
• Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada

  2024cites this paper
• Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes

  2024cites this paper
• English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology

  2024cites this paper
• Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities

  2023cites this paper
• Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study

  2023cites this paper
• Predictive performance of [18F]F-fibroblast activation protein inhibitor (FAPI)-42 positron emission tomography/computed tomography (PET/CT) in evaluating response of recurrent or metastatic gastrointestinal stromal tumors: complementary or alternative to [18F]fluorodeoxyglucose (FDG) PET/CT?

  2023cites this paper
• Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours

  2023cites this paper
• Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.

  2023cites this paper
• The patient's perspective on side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors.

  2023cites this paper
• Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis

  2023cites this paper
• Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib

  2023cites this paper
• Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor

  2023cites this paper
• Adjusting for time-varying treatment switches in randomized clinical trials: the danger of extrapolation and how to avoid it

  2023cites this paper
• Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data

  2022cites this paper
• Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report

  2022cites this paper
• A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor

  2022influential citation
• Combination of Type I and II tyrosine kinase inhibitors—avapritinib and sunitinib—in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report

  2022cites this paper
• Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study

  2022cites this paper
• Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis

  2022cites this paper
• Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib

  2022cites this paper
• Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature

  2022influential citation
• Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST) - a Systematic Review.

  2022cites this paper
• PET imaging of Gastrointestinal Stromal Tumors (GIST)

  2022cites this paper
• Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

  2021cites this paper
• Ripretinib for the treatment of advanced gastrointestinal stromal tumor

  2021cites this paper
• A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters

  2021cites this paper
• Gastrointestinal stromal tumours

  2021cites this paper
• Risk of Thrombocytopenia With Platelet‐Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta‐Analysis of Phase 2/3 Randomized, Controlled Trials

  2021cites this paper
• Cardio-oncology for the general cardiologist

  2021cites this paper
• Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors

  2020cites this paper
• Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic

  2020cites this paper
• Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.

  2020cites this paper
• Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries.

  2020cites this paper
• Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.

  2020cites this paper
• The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

  2020cites this paper
• Risk of hand-foot skin reaction associated with VEGFR-TKIs: a meta-analysis of 57 randomized controlled trials involving 24956 patients.

  2020cites this paper
• Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.

  2019cites this paper
• Gastrointestinal Stromal Tumors

  2019cites this paper
• Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

  2019cites this paper
• Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib

  2019cites this paper
• Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland

  2019cites this paper
• Translational investigations of novel and current antitumoral therapies in gastrointestinal stromal tumors

  2019cites this paper
• Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials

  2019cites this paper
• Gastrointestinal Stromal Tumor (GIST): Diagnosis and Treatment

  2019cites this paper
• Gastrointestinal stromal tumors

  2019cites this paper
• Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST)

  2019cites this paper
• Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

  2018cites this paper
• Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

  2018cites this paper
• Receptor Tyrosine Kinase-Targeted Cancer Therapy

  2018cites this paper
• Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials

  2018cites this paper
• Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States.

  2018cites this paper
• Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era

  2018cites this paper
• Translational insights into gastrointestinal stromal tumor and current clinical advances

  2018cites this paper
• Multimodality Therapy for Metastatic Gastrointestinal Stromal Tumor

  2017cites this paper
• Primary intraosseous squamous cell carcinoma in a dentigerous cyst

  2017cites this paper
• Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany

  2017cites this paper
• Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.

  2017influential citation
• Gastrointestinal stromal tumor (GIST) with liver metastases

  2017cites this paper
• Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

  2017cites this paper
• GIST: Sequencing Treatment and Case Report Evolution

  2017cites this paper
• Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center

  2017cites this paper
• Prognostic Factors for Advanced GIST

  2017cites this paper
• Gastric gastrointestinal stromal tumor: Does the newly proposed UICC TNM staging system provide better prognostic ability than the National Institutes of Health consensus criteria?

  2016cites this paper
• Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

  2016cites this paper
• Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

  2016cites this paper
• Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

  2016cites this paper
• Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents

  2016cites this paper
• Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study

  2016cites this paper
• Update on clinical research and state of the art management of patients with advanced sarcomas and GIST

  2016influential citation
• Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients

  2016cites this paper
• A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib

  2016cites this paper
• Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors

  2016cites this paper
• Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

  2016cites this paper
• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

  2016cites this paper
• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

  2016cites this paper
• Gastrointestinal Stromal Tumors

  2016cites this paper
• Molecular target therapy for gastrointestinal stromal tumors

  2015cites this paper
• Dose optimization of oral targeted therapies in oncology

  2015cites this paper
• Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib

  2015cites this paper
• Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.

  2015cites this paper
• Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.

  2015cites this paper
• Treatment switching in oncology trials and the acceptability of adjustment methods

  2015cites this paper
• Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy

  2015cites this paper
• Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

  2015cites this paper
• Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis

  2015influential citation
• Gastrointestinal Stromal Tumors (GIST)—Paving the Way for Modern Oncology—Epidemiology, Diagnosis, Treatment

  2015cites this paper
• Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

  2015cites this paper
• Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial

  2015cites this paper
• Gastrointestinal Stromal Tumour (GIST): Diagnosis and Treatment

  2015cites this paper
• Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor

  2015influential citation
• Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

  2014cites this paper